STOCK TITAN

Karuna Therapeutics, Inc. - $KRTX STOCK NEWS

Welcome to our dedicated page for Karuna Therapeutics news (Ticker: $KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karuna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karuna Therapeutics's position in the market.

Rhea-AI Summary
Karuna Therapeutics announced new efficacy, safety, and tolerability analyses from its EMERGENT program evaluating KarXT in adults with schizophrenia. The company submitted an NDA for KarXT for the treatment of schizophrenia to the FDA in September 2023. KarXT would represent the first new mechanism of action to treat schizophrenia in several decades if approved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
conferences acquisition
-
Rhea-AI Summary
Karuna Therapeutics, Inc. (NASDAQ: KRTX) will present at two upcoming investor conferences: Guggenheim 5th Annual Inflammation & Immunology Conference on November 7, 2023, and Stifel 2023 Healthcare Conference on November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
conferences
-
Rhea-AI Summary
Karuna Therapeutics to host conference call and webcast to review Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
Rhea-AI Summary
PureTech Health announces third quarter progress and upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
-
Rhea-AI Summary
Karuna Therapeutics announces new data supporting KarXT as a treatment option for schizophrenia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
conferences acquisition
-
Rhea-AI Summary
Karuna Therapeutics submits NDA to FDA for KarXT for schizophrenia treatment, could be first new mechanism in over 50 years if approved
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
Rhea-AI Summary
Karuna Therapeutics submits NDA to FDA for KarXT, a new treatment for schizophrenia. If approved, it will be the first novel pharmacological approach in decades. Supported by positive data from three trials showing significant symptom reduction. KarXT found to be well-tolerated with low discontinuation rates and no common side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
Rhea-AI Summary
Karuna Therapeutics, Inc. (NASDAQ: KRTX) announces upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
-
Rhea-AI Summary
Karuna Therapeutics, Inc. announced financial results for Q2 2023 and provided a business update. They are on track to submit an NDA for KarXT in schizophrenia with the FDA in Q3 2023, with a product launch in H2 2024. They also announced key leadership appointments and have $1.4 billion in cash expected to fund operations through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
Rhea-AI Summary
Karuna Therapeutics, Inc. (NASDAQ: KRTX) announces the appointment of Jonathan Rosin as Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Officer. These executive appointments are a key part of the company's transition to a fully integrated organization. Jonathan Rosin brings over 30 years of experience in human resources, organizational development, and talent management, while Jason Brown has extensive knowledge and experience in all aspects of the finance function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
Karuna Therapeutics, Inc.

Nasdaq:KRTX

KRTX Rankings

KRTX Stock Data

12.60B
36.27M
4.99%
86.32%
5.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About KRTX

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip